Abbott Laboratories Corporation

Children's Medical Center Corporation

Genentech, Inc.

Other

Harvard College

Abbvie Inc.

Pharm-eco Laboratories, Inc.

Nuchem Pharmaceuticals Inc.

Ion Pharmaceuticals, Inc.

Elan Pharmaceuticals, Inc.

F. Hoffmann-la Roche Ag

Minghua Sun

Chen Zhao

Adel M Moussa

Richard John Lombardy

Jose Alberto Halperin

Ying-Duo Gao

Yesh P Sachdeva

Carlo Brugnara

John J Clifford

Heather N Taft

Reem M Haidar

Eugene W Kelleher

Dale J Kempf

Darold L Madigan

Marlon D Cowart

Allan C Krueger

Ming Clinton Yeung

David J Grampovnik

Gary T Wang

Clarence J Maring

Xiaojing Wang

Larry L Klein

Guo Zhu Zheng

Kent D Stewart

Andrew Sharpe

Vincent L Giranda

Hui-Ju J Chen

Alastair James Hodges

Emile M Bellott

Vincent S Stoll

Yu Gui Gu

William J Flosi

Rudolf Fluckiger

Hing L Sham

Warren M Kati

Stephen Hanessian

Yuanwei Chen

Sheldon Wang

David A Degoey

Steven W Muchmore

Mark Froimowitz

Zhen Lin

April Kennedy

Emile M Bellot, Jr

Falguni M Kher

Lawrence A Black

John T Randolph

David A DeGoey

Wesley Peter Blackaby

Charles A Flentge

Keith F McDaniel

Lawrence Kolaczkowski

Paul E Wiedeman

Vickie H Tsui

Jason Burch

Peggy Huang

Xuehong Luo

Robert J Gregg

Mizio Matteucci

Yibo Xu

Reem M Haider

Michael H Zeldin

Frank L Wagenaar

Noah P Tu

Malken Bayrakdarian

Andrei William Konradi

Christopher Michael Semko

Anthony Ralph Haight

Geoff G Z Zhang

Darren B Dressen

Youssef L Bennani

Rodger F Henry

David M Barnes

Ahmad Y Sheikh

Simeon Bowers

Steven J Wittenberger

Albert W Garofalo

Michael S Dappen

Sou-Jen Chang

Anh P Truong

Danielle Aubele

Gary D Probst

Xiaochun Lou

Michael G Fickes

Xiaocong Michael Ye

Raymond Ng

Jianchio Wang

Peggy P Huang

William J; Flosi

Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein Ris a cyclic ether and X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use

Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use

A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

HIV protease inhibiting compounds

Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

Benzothiazole cyclobutyl amine derivatives

Octahydro-pyrrolo[3,4-b]pyrrole derivatives are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.

Octahydro-pyrrolo[3,4-B]pyrrole derivatives

The current invention provides compounds having a structure according to Formulae 1, 2, 3, and 4: wherein the A-ring, B-ring, C-ring, m, n, R, R, and Rare as described in the specification. The invention also provides pharmaceutical compositions comprising compounds of Formulae 1, 2, 3, and 4, as well as methods of treating cognitive disorders, such as Alzheimer's disease. The invention further provides intermediates useful in preparing the compounds of Formulae 1, 2, 3, and 4.

N-sulfonamido polycyclic pyrazolyl compounds

Octahydro-pyrrolo[3,4-b]pyrrole derivatives are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands, Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.

Octahydro-pyrrolo[3,4-b]pyrrole derivatives

The present invention provides a class of chemical compounds useful as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation, and in particular inflammatory diseases associated with unwanted cellular proliferation. The active compounds are substituted triaryl methane compounds or analogues thereof where one or more of the aryl groups is replaced with a heteroaryl, cycloalkyl or heterocycloalkyl group and/or the tertiary carbon atom is replaced with a different atom such as Si, Ge, N or P. the compounds inhibit mammalian cell proliferation, inhibit the Gardos channel of erythrocytes, reduce sickle erythrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation.

Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease

Azacyclosteroid histamine-3 receptor ligands, pharmaceutical compositions comprising such compounds, and methods for using such compounds and compositions are described herein.

Azacyclosteroid histamine-3 receptor ligands

The present invention provides substituted 3,3-diphenyl indole compounds, as well as analogues thereof, which are specific potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.

Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment or prevention of diseases characterized by abnormal cell proliferation

The present invention provides substituted 11-phenyl-dibenzazepine compounds which are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.

Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation

Growing community of inventors

Libertyville, IL, United States of America

Minghua Sun